151 related articles for article (PubMed ID: 35387686)
1. Dietetic intervention in psoriatic arthritis: the DIETA trial.
Leite BF; Morimoto MA; Gomes CMF; Klemz BNC; Genaro PS; Shivappa N; Hébert JR; Damasceno NRT; Pinheiro MM
Adv Rheumatol; 2022 Apr; 62(1):12. PubMed ID: 35387686
[TBL] [Abstract][Full Text] [Related]
2. Higher bodily adiposity, fat intake, and cholesterol serum levels are associated with higher disease activity in psoriatic arthritis patients: is there a link among fat and skin and joint involvement?
Leite BF; Morimoto MA; Gomes C; Klemz BNC; Genaro PS; Damasceno NRT; Szejnfeld VL; Pinheiro MM
Lipids Health Dis; 2020 Feb; 19(1):21. PubMed ID: 32028959
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
Mease P; Husni ME; Kafka S; Chakravarty SD; Harrison DD; Lo KH; Xu S; Hsia EC; Kavanaugh A
Arthritis Res Ther; 2020 Mar; 22(1):43. PubMed ID: 32143685
[TBL] [Abstract][Full Text] [Related]
4. Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis.
Nakagawa H; Tanaka Y; Sano S; Kameda H; Taniguchi A; Kashiwagi T; Kawaberi T; Kimura J; Morita A
Adv Ther; 2019 Mar; 36(3):691-707. PubMed ID: 30661197
[TBL] [Abstract][Full Text] [Related]
5. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study.
Klingberg E; Bilberg A; Björkman S; Hedberg M; Jacobsson L; Forsblad-d'Elia H; Carlsten H; Eliasson B; Larsson I
Arthritis Res Ther; 2019 Jan; 21(1):17. PubMed ID: 30635024
[TBL] [Abstract][Full Text] [Related]
6. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.
Kavanaugh A; McInnes IB; Krueger GG; Gladman D; Beutler A; Gathany T; Mack M; Tandon N; Han C; Mease P
Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1666-73. PubMed ID: 23666608
[TBL] [Abstract][Full Text] [Related]
8. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).
Mulder MLM; Vriezekolk JE; den Broeder N; Mahler EAM; Helliwell PS; van den Hoogen FHJ; den Broeder AA; Wenink MH
Trials; 2020 Feb; 21(1):155. PubMed ID: 32041657
[TBL] [Abstract][Full Text] [Related]
9. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
10. Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial.
Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Noonan L; Hsia EC
J Rheumatol; 2019 Jun; 46(6):595-602. PubMed ID: 30770519
[TBL] [Abstract][Full Text] [Related]
11. Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a
McInnes IB; Ferraccioli G; D'Agostino MA; Le Bars M; Banerjee S; Ahmad HA; Elbez Y; Mease PJ
RMD Open; 2019; 5(1):e000934. PubMed ID: 31245054
[TBL] [Abstract][Full Text] [Related]
12. Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.
Helliwell PS; Deodhar A; Gottlieb AB; Boehncke WH; Xu XL; Xu S; Wang Y; Hsia EC; Gladman DD; Ritchlin CT
Arthritis Care Res (Hoboken); 2020 Nov; 72(11):1579-1588. PubMed ID: 31421033
[TBL] [Abstract][Full Text] [Related]
13. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
[TBL] [Abstract][Full Text] [Related]
14. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT.
Mease PJ; Heckaman M; Kary S; Kupper H
J Rheumatol; 2013 May; 40(5):647-52. PubMed ID: 23504383
[TBL] [Abstract][Full Text] [Related]
15. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers.
Di Minno MN; Peluso R; Iervolino S; Russolillo A; Lupoli R; Scarpa R;
Ann Rheum Dis; 2014 Jun; 73(6):1157-62. PubMed ID: 23771989
[TBL] [Abstract][Full Text] [Related]
16. Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up.
Klingberg E; Björkman S; Eliasson B; Larsson I; Bilberg A
Arthritis Res Ther; 2020 Oct; 22(1):254. PubMed ID: 33092646
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.
Landewé R; Ritchlin CT; Aletaha D; Zhang Y; Ganz F; Hojnik M; Coates LC
Rheumatology (Oxford); 2019 Jun; 58(6):1025-1033. PubMed ID: 30608620
[TBL] [Abstract][Full Text] [Related]
18. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
Helliwell P; Coates LC; FitzGerald O; Nash P; Soriano ER; Elaine Husni M; Hsu MA; Kanik KS; Hendrikx T; Wu J; Kudlacz E
Arthritis Res Ther; 2018 Oct; 20(1):242. PubMed ID: 30373651
[TBL] [Abstract][Full Text] [Related]
19. Gender does not make a difference in "composite psoriatic disease activity index (CPDAI)" in patients with psoriatic arthritis.
Kenar G; Yarkan H; Zengin B; Can G; Birlik M; Önen F
Rheumatol Int; 2018 Nov; 38(11):2069-2076. PubMed ID: 30194455
[TBL] [Abstract][Full Text] [Related]
20. Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study.
Kavanaugh A; van der Heijde D; Beutler A; Gladman D; Mease P; Krueger GG; McInnes IB; Helliwell P; Coates LC; Xu S
Arthritis Care Res (Hoboken); 2016 Feb; 68(2):267-74. PubMed ID: 25779603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
